Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
Caspase 3
|
---|---|
ln Vitro |
In ASG cells, Cimiside E (30-90 μM; 24 h) inhibits the cell cycle and causes apoptosis[1]. Cimiside E (30-90 μM; 12-48 h) possesses anti-proliferative action and significant cytotoxicity against AGS cells [1]. Cimiside E (30-90 μM; 3-24 h) mediates the caspase cascade, raises the Bax/Bcl-2 ratio, decreases mutant p53 and procaspase 3 protein levels, and promotes DNA fragmentation in ASG cells (15-60 μM; 1-6 h) and activates FasL expression at 3 h and Fas at 1 h[1].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: Cimiside E. AGS cells Tested Concentrations: 30 μM, 60 μM, and 90 μM Incubation Duration: 3 h, 6 h, 12 h, and 24 h Experimental Results: Increased the ratio of Bax/Bcl-2 expression from 60 μM. diminished mutant type (mt) p53 levle from 12 h at 30 μM. Suppressed the protein level of procaspase 3 in a dose-dependent manner from 30 μM. Cell Proliferation Assay[1] Cell Types: Cimiside E. AGS cells Tested Concentrations: 30 μM, 60 μM, and 90 μM Incubation Duration: 12 h, 24 h, and 48 h Experimental Results: Inhibited ASG cells proliferation with IC50s of 28.7, 14.6 and 8.1 µM, respectively, for 30 μM, 60 μM, and 90 μM treatment. Cell Cycle Analysis[1] Cell Types: Cimiside E. AGS cells Tested Concentrations: 30 μM, 60 μM, and 90 μM Incubation Duration: 3 h, 6 h, and 24 h Experimental Results: Induced cell cycle arrest at S phase in a low concentration (30 μM), but arrested cell cycle at G2/M phase in higher concentration (60 μM and 90 μM ). |
References |
[1]. Guo LY, et al. Cimiside E arrests cell cycle and induces cell apoptosis in gastric cancer cells. Arch Pharm Res. 2009 Oct;32(10):1385-92.
[2]. Jamróz MK, et al. One new and six known triterpene xylosides from Cimicifuga racemosa: FT-IR, Raman and NMR studies and DFT calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jul;93:10-8. |
Molecular Formula |
C35H54O8
|
---|---|
Molecular Weight |
602.80
|
CAS # |
154822-57-8
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C=C(C)[C@H]1[C@H]2C[C@@H](C)[C@@H]3[C@@]4(C)CC[C@]56C[C@]76CC[C@@H](C(C)(C)[C@@H]7CC[C@H]5[C@]4(C)[C@H]([C@@]3(O2)O1)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6589 mL | 8.2946 mL | 16.5893 mL | |
5 mM | 0.3318 mL | 1.6589 mL | 3.3179 mL | |
10 mM | 0.1659 mL | 0.8295 mL | 1.6589 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.